Order of the Government of the Republic of Kazakhstan "About some questions of tax exemption on value added in health sector"

ORDER OF THE GOVERNMENT OF THE REPUBLIC OF KAZAKHSTAN

of December 31, 2025 No. 1203

About some questions of tax exemption on value added in health sector

According to the subitem 28) of Article 474 and the subitem 17) of article 479 of the Tax Code of the Republic of Kazakhstan the Government of the Republic of Kazakhstan DECIDES:

1. Approve enclosed:

1) the list of medical services, including the subject of health care having the license for medical activities within the guaranteed amount of free medical care and the compulsory medical insurance rendered in complex according to the legislation of the Republic of Kazakhstan and also for treatment of orphan and socially important diseases which turnovers on realization are exempted from the value added tax;

2) the list of medicines within the guaranteed amount of free medical care and compulsory medical insurance, and also for treatment of orphan and socially important diseases which turnovers on realization are exempted from the value added tax;

3) the list of medicines within the guaranteed amount of free medical care and compulsory medical insurance, and also for treatment of orphan and socially important diseases which import is exempted from the value added tax;

4) Rules of application of tax exemption on value added when importing medicines within the guaranteed amount of free medical care and compulsory medical insurance, and also for treatment of orphan and socially important diseases.

2. This resolution becomes effective since January 1, 2026 and is subject to official publication.

Prime Minister of the Republic of Kazakhstan

O. Bektenov

Approved by the Order of the Government of the Republic of Kazakhstan of December 31, 2025, No. 1203

The list of medical services, including the subject of health care having the license for medical activities within the guaranteed amount of free medical care, the compulsory medical insurance rendered in complex according to the legislation of the Republic of Kazakhstan and also for treatment of orphan and socially important diseases which turnovers on realization are exempted from the value added tax

1. Medical services within the guaranteed amount of free medical care, compulsory medical insurance:

1) emergency medical service, including with involvement of medical aircraft;

2) primary health care to the adult and (or) children's population in out-patient, hospital-replacing conditions and at home on specialties;

3) consulting and diagnostic help to the adult and (or) children's population with specialties, including:

diagnostics is radio isotope, radiological, ultrasonic, functional, endoscopic;

laboratory diagnostics (bacteriological, biochemical, immunological researches, all-clinical, serological, cytologic trials);

histology;

laboratory genetics;

anesthesiology and resuscitation;

obstetric case;

obstetrics and gynecology (except for uses of auxiliary reproductive technologies and abortion);

obstetrics and gynecology (use of auxiliary reproductive technologies and abortion);

obstetrics and gynecology (use of abortion);

allergology and immunology;

angiosurgery;

aviation and space medicine;

vaccination (carrying out preventive inoculations);

gastroenterology;

hematology;

geriatrics;

clinical dietology;

dermatovenereology;

infectious diseases;

cardiology;

heart surgery;

clinical pharmacology;

radiation therapy;

medical genetics;

medicine of emergency situations and catastrophic crashes;

medico-public assistance;

physical medicine and rehabilitation (physical therapy, massage, physiotherapy exercises, balneology);

narcology, psychotherapy, sexual pathology, medical psychology;

urgent medicine;

neonatology;

neurology;

nephrology;

neurosurgery;

otorhinolaryngology;

ophthalmology;

orthodontics;

osteopathy;

general medical practice;

general surgery: thoracic, abdominal, coloproctology, maxillofacial;

oncology and hematology;

oncology radiation;

pathological anatomy;

professional pathology;

pediatrics;

pulmonology;

plastic surgery (in case of congenital defects at children);

psychiatry;

rheumatology;

radiology;

medical rehabilitation;

stomatology (therapeutic, surgical, orthodontic);

nurse business;

family medicine;

sports medicine;

therapy;

transfusiology;

transplantology;

traumatology orthopedics;

traditional medicine (homeopathy, girudoterapiya, manual therapy, reflexotherapy, phytotherapy and treatment by means of natural origin);

clinical toxicology;

urology and andrology;

phthisiology;

endocrinology;

4) specialized medical care in out-patient conditions on specialties, including:

anesthesiology and resuscitation;

obstetric case;

obstetrics and gynecology (except for uses of auxiliary reproductive technologies and abortion);

obstetrics and gynecology (use of auxiliary reproductive technologies and abortion);

obstetrics and gynecology (use of abortion);

allergology and immunology;

angiosurgery;

aviation and space medicine;

vaccination (carrying out preventive inoculations);

gastroenterology;

hematology;

geriatrics;

clinical dietology;

dermatovenereology;

infectious diseases;

cardiology;

heart surgery;

radiation therapy;

medical genetics;

medico-public assistance;

physical medicine and rehabilitation (physical therapy, massage, physiotherapy exercises, balneology);

narcology, psychotherapy, sexual pathology, medical psychology;

neonatology;

neurology;

nephrology;

neurosurgery;

otorhinolaryngology;

ophthalmology;

orthodontics;

osteopathy;

general medical practice;

general surgery: thoracic, abdominal, coloproctology, maxillofacial;

oncology;

pathological anatomy;

professional pathology;

pediatrics;

pulmonology;

plastic surgery (in case of congenital defects at children);

psychiatry;

rheumatology;

medical rehabilitation;

stomatology (therapeutic, surgical, orthodontic);

nurse business;

sports medicine;

therapy;

transfusiology;

transplantology;

traumatology orthopedics;

traditional medicine (homeopathy, girudoterapiya, manual therapy, reflexotherapy, phytotherapy and treatment by means of natural origin);

clinical toxicology;

urology;

phthisiology;

endocrinology;

5) the stationary help and (or) the hospital-replacing help to the adult, and (or) the children's population on specialties, and also specialized medical care using high-technology medical services, including:

diagnostics is radio isotope, radiological, ultrasonic, functional, endoscopic, pathological anatomy;

laboratory diagnostics (bacteriological, biochemical, immunological researches, all-clinical, serological, cytologic trials);

histology;

laboratory genetics;

obstetric case;

obstetrics and gynecology (except for uses of auxiliary reproductive technologies and abortion);

obstetrics and gynecology (use of auxiliary reproductive technologies and abortion); obstetrics and gynecology (use abortion);

allergology and immunology;

anesthesiology and resuscitation;

angiosurgery;

aviation and space medicine;

vaccination (carrying out preventive inoculations);

gastroenterology;

hematology;

geriatrics;

clinical dietology;

dermatovenereology;

infectious diseases;

cardiology;

heart surgery;

radiation therapy;

medical genetics;

medico-public assistance;

physical medicine and rehabilitation (physical therapy, massage, physiotherapy exercises, balneology);

narcology, psychotherapy, sexual pathology, medical psychology;

neonatology;

neurology;

nephrology;

neurosurgery;

otorhinolaryngology;

ophthalmology;

orthodontics;

osteopathy;

general medical practice;

general surgery: thoracic, abdominal, coloproctology, maxillofacial;

oncology;

pathological anatomy;

professional pathology;

pediatrics;

portable medical complex;

pulmonology;

plastic surgery (in case of congenital defects at children);

psychiatry:

rheumatology;

medical rehabilitation;

stomatology (therapeutic, surgical, orthodontic);

nurse business;

sports medicine;

therapy;

transfusiology;

transplantology;

traumatology orthopedics;

traditional medicine (homeopathy, girudoterapiya, manual therapy, reflexotherapy, phytotherapy and treatment by means of natural origin);

clinical toxicology;

urology;

phthisiology;

endocrinology;

nuclear medicine;

treatment by radio pharmaceutical medicines;

6) procurement, preservation, conversion, storage, realization of blood, its components and haematopoietic stem cells;

7) palliative care;

8) examination and medical examination:

medical examination;

examination of temporary disability and professional suitability (military-medical examination, medical and flight);

examination of communication of disease with profession and consequences of the Semipalatinsk test nuclear test site;

medical examination on state of intoxication (alcoholic, narcotic or other toxic);

9) additional amount of medical care for persons containing in pre-trial detention centers and organizations of criminal and executive (penitentiary) system.

2. Medical services for treatment of socially important and orphan diseases regardless of source of their payment:

1) emergency medical service, including with involvement of medical aircraft;

2) specialized medical care in out-patient conditions;

3) primary health care to the adult and (or) children's population in out-patient, hospital-replacing conditions and at home on specialties;

4) consulting and diagnostic help to the adult and (or) children's population with specialties, including:

diagnostics is radio isotope, radiological, ultrasonic, functional, endoscopic;

laboratory diagnostics (bacteriological, biochemical, immunological researches, all-clinical, serological, cytologic trials);

histology;

laboratory genetics;

medical examinations: routine medical examinations, screening researches;

medical rehabilitation;

palliative care and sisterly leaving;

medico-public assistance;

5) the stationary help and (or) the hospital-replacing help to the adult, and (or) the children's population, including specialized medical care using high-technology medical services, including:

diagnostics is radio isotope, radiological, ultrasonic, functional, endoscopic, pathological anatomy;

laboratory diagnostics (bacteriological, biochemical, immunological researches, all-clinical, serological, cytologic trials);

medical examination and medical examination;

medical rehabilitation;

palliative care and sisterly leaving;

medico-public assistance;

6) examination and medical examination, including:

medical examination on state of intoxication (alcoholic, narcotic or other toxic);

examination of communication of diseases with profession and consequences of the Semipalatinsk test nuclear test site;

examination of temporary disability and professional suitability (military-medical examination, medical and flight);

7) additional amount of medical care for persons containing in pre-trial detention centers and organizations of criminal and executive (penitentiary) system.

Approved by the Order of the Government of the Republic of Kazakhstan of December 31, 2025, No. 1203

The list of medicines within the guaranteed amount of free medical care and compulsory medical insurance, and also for treatment of orphan and socially important diseases which turnovers on realization are exempted from the value added tax

№ payment order	Code of the commodity nomenclature of foreign economic activity of the Eurasian Economic Union	Description of goods
Group 15. Fats and oils of animal or phytogenesis and products of their splitting; ready food fats; wax of animal or phytogenesis
1	1504 20	cod-liver oil, oil and their fractions, except fat from liver of fishes, used in case of production of pharmaceutical products
2	1515	the vegetable oils and their fractions used in case of production of pharmaceutical products
Group 17. Sugar and confectionery from sugar
3	1702	other sugar, including chemically net lactose, maltose, glucose and fructose, in firm condition, used in case of production of pharmaceutical products
Group 21. Different foodstuff
4	2106 90 980 3	the mixes of vitamins and mineral substances intended for the balanced amendment to food, used for prevention and treatment of diseases
Group 25. Salt; sulfur; lands and stone; plaster materials, lime and cement
5	2501 00	sodium chloride net, used in case of production of pharmaceutical products
Group 27. Fuel mineral, oil and products of their distillation; bituminous substances; wax mineral
6	2712 10 900 0	the other petroleum jelly used in case of production of pharmaceutical products
7	2712 20	paraffin with content of oils of less 0,75 Mas. the % used in case of production of pharmaceutical products
Group 28. Products of inorganic chemistry; connections inorganic or organic precious metals, rare-earth metals, radioactive elements or isotopes
8	group 28	products of inorganic chemistry; connections inorganic or organic precious metals, rare-earth metals, radioactive elements or isotopes, used in case of production of pharmaceutical, medical products, and the distilled, konduktometrichesky water and water of similar purity used for the medical purposes
Group 29. Organic chemical compounds
9	group 29	organic chemical compounds, natural or synthesized, used in case of production of pharmaceutical, medical products; for application in sterilizers
Group 30. Pharmaceutical products
10	group 30	pharmaceutical products
№	Code anatomo - therapeutic and chemical classification of medicines	Name of medicine (international non-proprietary name or structure)	Dosage form
1	A01AB09	Mikonazol	gel oral
2	A01AB18	Klotrimazol **	solution for local application, 1%, 15 ml
3	A02AF02	Simple combination of salts and carminative medicines	tablet
4	A02AF02	Simple combination of salts and carminative medicines	suspension for intake, 170 ml
5	A02AF02	Simple combination of salts and carminative medicines	suspension for intake, 10 ml
6	A02AF02	Simple combination of salts and carminative medicines	suspension for intake, 300 ml
7	A02BA02	Ranitidine **	tablet, 150 mg
8	A02BA03	Famotidin **	the powder lyophilized for solution for injections, 20 mg
9	A02BA03	Famotidin **	tablet, 40 mg
10	A02BA03	Famotidin **	tablet, 20 mg
11	A02BC01	Omeprazol **	capsule, 10 mg
12	A02BC01	Omeprazol **	capsule, 20 mg
13	A02BC01	Omeprazol **	capsule, 40 mg
14	A02BC01	Omeprazol **	lyophilisate for solution for intravenous administration, 40 mg
15	A02BC01	Omeprazol **	powder for suspension of intake, 20 mg
16	A02BC02	Pantoprazol **	the powder lyophilized for solution for injections, 40 mg
17	A02BC02	Pantoprazol **	powder for solution for injections, 40 mg
18	A02BC02	Pantoprazol **	tablet, 40 mg
19	A02BC02	Pantoprazol **	tablet, 20 mg
20	A02BC02	Pantoprazol **	solution lyophilisate for injections and infusions of 40 mg
21	A02BC03	Lansoprazol **	capsule, 30 mg
22	A02BC04	Rabeprazol **	tablet, 10 mg
23	A02BC04	Rabeprazol **	tablet, 20 mg
24	A02BC04	Rabeprazol **	capsule, 10 mg
25	A02BC04	Rabeprazol **	capsule, 20 mg
26	A02BC05	Ezomeprazol **	lyophilisate for solution for intravenous administration, 40 mg
27	A02BC05	Ezomeprazol **	the powder lyophilized for solutions for injections/infusions, 40 mg
28	A02BC05	Ezomeprazol **	tablet, 40 mg
29	A02BC05	Ezomeprazol **	capsule, 40 mg
30	A02BC05	Ezomeprazol **	capsule, 20 mg
31	A02BC05	Ezomeprazol **	tablet, 20 mg
32	A02BX05	Bismuth subcitrate	tablet, 120 mg
33	A03AA	Synthetic holinoblokator - air with tertiary amino group	solution for injections, 0,2 of % of 1 ml
34	A03AA04	Mebeverin	capsule, 200 mg
35	A03AD01	Papaverine	tablet, 0,04 of
36	A03AD01	Papaverine	suppositories, 20 mg
37	A03AD01	Papaverine	solution for injections, 20 mg/ml 2 ml
38	A03AD02	Drotaverin **	solution for injections, 20 mg/ml 2 ml
39	A03AD02	Drotaverin **	tablet, 40 mg
40	A03AD02	Drotaverin **	suppositories, 40 mg
41	A03AD02	Drotaverin **	tablet, 80 mg
42	A03AX13	Silicones	capsule, 40 mg
43	A03AX13	Silicones	tablet, 125 mg
44	A03AX13	Silicones	suspension for oral application, 40 mg/ml 30 ml
45	A03AX13	Silicones	emulsion for intake of 66.66 mg/ml 30 ml
46	A03AX13	Silicones	film, mg 62,5
47	A03AX13	Silicones	drops for intake, 40 mg
48	A03BA01	Atropine **	solution for injections, 1mg/ml 1 ml
49	A03BB01	Butilskopolamin *	tablet, 10 mg
50	A03FA01	Metoklopramid **	solution for injections, 5 mg/ml 2 ml
51	A03FA01	Metoklopramid **	tablet, 10 mg
52	A03FA03	Domperidon	tablet, 10 mg
53	A03FA03	Domperidon	drops for intake, 5 ml
54	A03FA03	Domperidon	syrup, 30 ml
55	A03FA03	Domperidon	syrup, 60 ml
56	A03FA03	Domperidon	suspension for intake, 1 mg/ml 60 ml
57	A03FA03	Domperidon	suspension for intake, 1 mg/ml 100 ml
58	A03FA03	Domperidon	suspension for intake, 1 mg/ml 30 ml
59	A03FA03	Domperidon	suspension for intake, 1 mg/ml 200 ml
60	A04AA01	Ondansetron **	solution for injections, 2 mg/ml 2 ml
61	A04AA01	Ondansetron **	solution for injections, 2 mg/ml 4 ml
62	A04AA01	Ondansetron **	tablet, 4 mg
63	A04AA01	Ondansetron **	tablet, 8 mg
64	A04AA02	Granisetron **
65	A04AD12	Aprepitant **	capsule, 125 mg
66	A04AD12	Aprepitant **	capsule, 80 mg
67	A05AA02	Ursodezoksikholevy acid **	capsule, 250 mg
68	A05AA02	Ursodezoksikholevy acid **	capsule, 300 mg
69	A05AA02	Ursodezoksikholevy acid **	capsule, 450 mg
70	A05AA02	Ursodezoksikholevy acid **	capsule, 150 mg
71	A05AA02	Ursodezoksikholevy acid **	tablet, 300 mg
72	A05AA02	Ursodezoksikholevy acid **	tablet, 250 mg
73	A05AA02	Ursodezoksikholevy acid **	tablet, 500 mg
74	A05AA02	Ursodezoksikholevy acid **	tablet, 150 mg
75	A05AA04	Obetikholevy acid	tablet, 5 mg
76	A05AA04	Obetikholevy acid	tablet, 10 mg
77	A06AB02	Bisakodil	suppositories are rectal, 10 mg
78	A06AB02	Bisakodil	tablet, 5 mg
79	A06AB08	Sodium pikosulfat **	drops for intake of 7,5 of mg of 15 ml
80	A06AB08	Sodium pikosulfat **	drops for intake of 7,5 of mg of 30 ml
81	A06AB08	Sodium pikosulfat **	tablet, mg 7,5
82	A06AB08	Sodium pikosulfat **	drops for intake of 7,5 of mg of 10 ml
83	A06AB08	Sodium pikosulfat **	drops for intake of 7,5 of mg of 25 ml
84	A06AB08	Sodium pikosulfat **	drops for intake of 7,5 of mg of 20 ml
85	A06AB58	Sodium pikosulfat in combination with other medicines	powder for solution of oral application, 10 mg / 3,5 of / 12
86	A06AB58	Sodium pikosulfat in combination with other medicines	powder for solution of oral application, 10 mg / 10,97 g/3,5 of
87	A06AD04	Magnesium sulfate **	powder, 25 g
88	A06AD04	Magnesium sulfate **	powder, 50 g
89	A06AD04	Magnesium sulfate **	powder, 100 g
90	A06AD04	Magnesium sulfate **	powder, 70 g
91	A06AD11	Laktuloza **	syrup, 667 g/l 1000 ml
92	A06AD11	Laktuloza **	syrup, 667 g/l 500 ml
93	A06AD11	Laktuloza **	syrup, 667 g/l 250 ml
94	A06AD11	Laktuloza **	syrup, 667 g/l 200 ml
95	A06AD11	Laktuloza **	syrup, 667 mg/ml 200 ml
96	A06AD11	Laktuloza **	syrup, 667 mg/ml 1000 ml
97	A06AD11	Laktuloza **	syrup, 667 mg/ml 500 ml
98	A06AD11	Laktuloza **	syrup, 67 g / 100 ml of 120 ml
99	A06AD11	Laktuloza **	syrup, 66,7 of / 100 ml
100	A06AD11	Laktuloza **	syrup, 667 mg/ml 250 ml
101	A06AD15	Macrogoal	powder for solution of intake, 10 g
102	A06AD65	Macrogoal in combination with other medicines	powder for intake solution
103	A06AG04	Glitserol	rectal solution, 3 g
104	A06AG04	Glitserol	rectal solution, 9 g
105	A06AG04	Glitserol	rectal solution, ml 7,5
106	A06AG04	Glitserol	rectal solution, 4 ml
107	A06AX03	Lubiproston	capsule, 8 mkg
108	A06AX03	Lubiproston	capsule, 24 mkg
109	A06AX05	Prukaloprid
110	A07AA02	Nystatin **	tablet, 500 000 ED
111	A07AA02	Nystatin **	tablet, 250 000 ED
112	A07AA06	Paromomitsina sulfate *
113	A07AA11	Rifaksimin **	tablet, 200 mg
114	A07AA12	Fidaksomitsin	tablet, 200 mg
115	A07BA01	Absorbent carbon	tablet, 250 mg
116	A07BA01	Absorbent carbon	capsule, 200 mg
117	A07CA	Regidratanta for oral administration	solution powder for intake of 27,9 of
118	A07CA	Regidratanta for oral administration	solution powder for intake of 20,5 of
119	A07CA	Regidratanta for oral administration	solution powder for intake of 18,9 of
120	A07CA	Regidratanta for oral administration	solution powder for intake of 10,7 of
121	A07DA03	Loperamide	capsule, 2 mg
122	A07DA03	Loperamide	tablet, 2 mg
123	A07EA06	Budesonid **	tablet, 9 mg
124	A07EA06	Budesonid **	capsule, 3 mg
125	A07EC01	Sulfasalazin	tablet, 500 mg
126	A07EC02	Mesalazin	suppositories, 1000 mg
127	A07EC02	Mesalazin	tablet, 500 mg
128	A07EC02	Mesalazin	suspension of rectal, 1 g / 100 ml of 100 ml
129	A07EC02	Mesalazin	granules, 2 g
130	A07EC02	Mesalazin	tablet, 1,2 of
131	A07EC02	Mesalazin	tablet, 400 mg
132	A07EC02	Mesalazin	granules, 1 g
133	A07EC02	Mesalazin	tablet, 1 g
134	A08AB01	Orlistat	capsule, 120 mg
135	A08AB01	Orlistat	tablet, 120 mg
136	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 3 500 ED
137	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 10 000 ED
138	A09AA02	Multienzymes (lipase, protease, etc.) **	capsule, 10 000 ED
139	A09AA02	Multienzymes (lipase, protease, etc.) **	capsule, 25 000 ED
140	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 250 mg
141	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 8000 ED
142	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 25 ED
143	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 25 ED
144	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, mg 212,5
145	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, 0,24 of
146	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, mg 279,44
147	A09AA02	Multienzymes (lipase, protease, etc.) **	capsule, 400 mg
148	A09AA02	Multienzymes (lipase, protease, etc.) **	tablet, mg 89,36
149	A10AB01	Insulin human **	solution for injections, 100 ME/ml of 3 ml
150	A10AB01	Insulin human **	solution for injections, 100 ME/ml of 10 ml
151	A10AB04	Insulin lizpro	solution for injections, 100 ME/ml of 3 ml
152	A10AB04	Insulin lizpro	solution for injections, 100 ME/ml of 10 ml
153	A10AB05	Insulin aspart	solution for injections, 100 PIECES/ml 3 ml
154	A10AB05	Insulin aspart	solution for injections, 100 PIECES/ml 10 ml
155	A10AB06	Insulin glulizin	solution for injections, 100 PIECES/ml 3 ml
156	A10AC01	Insulin human **	suspension for hypodermic introduction, 100 PIECES/ml 3 ml
157	A10AC01	Insulin human **	suspension for hypodermic introduction, 100 PIECES/ml 10 ml
158	A10AC01	Insulin human **	solution for injections, 100 PIECES/ml 10 ml
159	A10AC01	Insulin human **	solution for injections, 100 PIECES/ml 3 ml
160	A10AC01	Insulin human **	solution for injections, 100 PIECES/ml 3 ml
161	A10AD01	Insulin (human)	suspension for hypodermic introduction, 100 ME/ml of 3 ml
162	A10AD01	Insulin (human)	suspension for hypodermic introduction, 100 PIECES/ml 10 ml
163	A10AD01	Insulin (human)	suspension for hypodermic introduction, 100 ME/ml of 10 ml
164	A10AD04	Insulin lizpro	suspension for hypodermic introduction, 100 ME/ml of 3 ml
165	A10AD05	Insulin aspart	suspension for hypodermic introduction, 100 PIECES/ml 3 ml
166	A10AD06	Insulin degludek and insulin aspart	solution for injections, 100 PIECES/ml
167	A10AE04	Insulin glargin	solution for injections, 300 PIECES/ml of 1,5 of ml
168	A10AE04	Insulin glargin	solution for injections, 100 PIECES/ml 3 ml
169	A10AE05	Insulin detemir	solution for hypodermic introduction, 100 PIECES/ml 3 ml
170	A10AE06	Insulin degludek	solution for injection, 100 PIECES/ml 3 ml
171	A10AE54	Insulin glargin and liksisenatid	solution for hypodermic introduction, 100 PIECES/ml + 50 mkg/ml
172	A10AE54	Insulin glargin and liksisenatid	solution for hypodermic introduction, 100 PIECES/ml + 33 mkg/ml
173	A10AE56	Insulin degludek and liraglutid	solution for injections, 100 PIECES/ml + mg/ml 3,6
174	A10BA02	Metformin	tablet, 500 mg
175	A10BA02	Metformin	tablet, 850 mg
176	A10BA02	Metformin	tablet, 1000 mg
177	A10BA02	Metformin	tablet, 750 mg
178	A10BB01	Glibenclamide	tablet, mg 3,5
179	A10BB01	Glibenclamide	tablet, 5 mg
180	A10BB09	Gliclazide	tablet, 60 mg
181	A10BB09	Gliclazide	tablet, 80 mg
182	A10BB09	Gliclazide	tablet, 30 mg
183	A10BB12	Glimepirid	tablet, 1 mg
184	A10BB12	Glimepirid	tablet, 2 mg
185	A10BB12	Glimepirid	tablet, 3 mg
186	A10BB12	Glimepirid	tablet, 4 mg
187	A10BB12	Glimepirid	tablet, 5 mg
188	A10BB12	Glimepirid	tablet of 6 mg
189	A10BD02	Metformin and sulfonamides	tablet, 500 mg / 2 mg
190	A10BD02	Metformin and sulfonamides	tablet, 500 mg / 5 mg
191	A10BD02	Metformin and sulfonamides	tablet, 500 mg / 2,5 of mg
192	A10BD07	Metformin and Sitagliptin	tablet, 500 mg / 50 mg
193	A10BD07	Metformin and Sitagliptin	tablet, 850 mg / 50 mg
194	A10BD07	Metformin and Sitagliptin	tablet, 1000 mg / 50 mg
195	A10BD08	Metformin and Vildagliptin	tablet, 850 mg / 50 mg
196	A10BD08	Metformin and Vildagliptin	tablet, 1000 mg / 50 mg
197	A10BD11	Metformin and Linagliptin	tablet, 1000 mg / 2,5 of mg
198	A10BD11	Metformin and Linagliptin	tablet, 850 mg / 2,5 of mg
199	A10BD15	Metformin and dapagliflozin	tablet, 1000 mg / 5 mg
200	A10BD15	Metformin and dapagliflozin	tablet, 1000 mg / 10 mg
201	A10BD15	Metformin and dapagliflozin	tablet, 500 mg / 10 mg
202	A10BD16	Metformin and Kanagliflozin
203	A10BD20	Metformin and Empagliflozin
204	A10BF01	Acarbose
205	A10BG03	Pioglitazon	tablet, 15 mg
206	A10BG03	Pioglitazon	tablet, 30 mg
207	A10BH01	Sitagliptin	tablet, 100 mg
208	A10BH01	Sitagliptin	tablet, 25 mg
209	A10BH01	Sitagliptin	tablet, 50 mg
210	A10BH02	Vildagliptin	tablet, 50 mg
211	A10BH03	Saksagliptin
212	A10BH04	Alogliptin	tablet, mg 12,5
213	A10BH04	Alogliptin	tablet, 25 mg
214	A10BH05	Linagliptin	tablet, 5 mg
215	A10BJ01	Eksenatid	powder with the solvent for suspension for hypodermic introduction, 2 mg / ml 0,65
216	A10BJ01	Eksenatid	suspension for hypodermic introduction, 2 mg / ml 0,85
217	A10BJ02	Liraglutid	solution for hypodermic introduction, 6 mg/ml 3 ml
218	A10BJ05	Dulaglutid	solution for hypodermic introduction, ml mg/0,5 0,75
219	A10BJ05	Dulaglutid	solution for hypodermic introduction, ml mg/0,5 1,5
220	A10BJ06	Semaglutid	solution for hypodermic introduction, mg/ml 1,34 (the syringe handle 0,25 of mg or 0,5 of mg/dose), ml 1,5
221	A10BJ06	Semaglutid	solution for hypodermic introduction, mg/ml 1,34 (the syringe handle of 1 mg / dose), 3 ml
222	A10BJ06	Semaglutid	tablet, 3 mg
223	A10BJ06	Semaglutid	tablet, 7 mg
224	A10BJ06	Semaglutid	tablet, 14 mg
225	A10BK01	Dapagliflozin	tablet, 10 mg
226	A10BK01	Dapagliflozin	tablet, 5 mg
227	A10BK02	Kanagliflozin	tablet, 100 mg
228	A10BK02	Kanagliflozin	tablet, 300 mg
229	A10BK03	Empagliflozin	tablet, 10 mg
230	A10BK03	Empagliflozin	tablet, 25 mg
231	A10BX02	Repaglinid	tablet, 2 mg
232	A10BX02	Repaglinid	tablet, 1 mg
233	A10BX10	Liksisenatid	solution for injections, 0,05 of mg/ml of 3 ml
234	A10BX10	Liksisenatid	solution for injections, 0,1 of mg/ml of 3 ml
235	A11CA01	Retinolum	capsule, 33 000 ME
236	A11CC01	Ergokaltsiferol	solution for oral application, 0,125 of % of 10 ml
237	A11CC02	Digidrotakhisterol
238	A11CC03	Alfakaltsidol	capsule, mkg 0,25
239	A11CC03	Alfakaltsidol	capsule, mkg 0,5
240	A11CC03	Alfakaltsidol	capsule, 1 mkg
241	A11CC05	Kolekaltsiferol	drops for intake, 4000 ME/ml of 10 ml
242	A11CC05	Kolekaltsiferol	drops for intake, 2800 ME/ml of 15 ml
243	A11CC05	Kolekaltsiferol	drops for intake, 15 000 ME/ml of 10 ml
244	A11CC05	Kolekaltsiferol	drops for intake of 0,5 of mg/ml of 10 ml
245	A11CC05	Kolekaltsiferol	tablet, 50000 ME
246	A11DA01	Thiamine **	solution for injections, 50 mg/ml 1 ml
247	A11GA01	Ascorbic acid **	solution for injections, 50 mg/ml 1 ml
248	A11GA01	Ascorbic acid **	solution for injections, 50 mg/ml 2 ml
249	A11GA01	Ascorbic acid **	drops for intake, 100 mg/ml 10 ml
250	A11GA01	Ascorbic acid **	drops for intake, 100 mg/ml 30 ml
251	A11GA01	Ascorbic acid **	solution for injections, 100 mg/ml 2 ml
252	A11GA01	Ascorbic acid **	tablet, 500 mg
253	A11GA01	Ascorbic acid **	dragee, 50 mg
254	A11GA01	Ascorbic acid **	tablet, 25 mg
255	A11HA02	Pyridoxine **	solution for injections, 50 mg/ml 1 ml
256	A11HA03	Tocopherol	capsule, 100 ME
257	A11HA03	Tocopherol	capsule, 200 mg
258	A11HA03	Tocopherol	capsule, 400 mg
259	A12AA03	Calcium gluconate **	solution for injections, 100 mg/ml 10 ml
260	A12AA03	Calcium gluconate **	solution for injections, 100 mg/ml 5 ml
261	A12AA03	Calcium gluconate **	solution for injections, 10 mg/ml 5 ml
262	A12AA03	Calcium gluconate **	tablet, 500 mg
263	A14AB01	Nandrolon	solution for injections, 50 mg/ml 1 ml
264	A16AA01	Left carnitine	solution for intake, 1 g / 10 ml of 10 ml
265	A16AA01	Left carnitine	solution for intravenous administration, 200 mg/ml 5 ml
266	A16AA01	Left carnitine	solution for injections, 1 g / 5мл
267	A16AA01	Left carnitine	solution for intake, 100 mg/ml 10 ml
268	A16AA01	Left carnitine	solution for intake, 2 g / 10 ml of 10 ml
269	A16AA01	Left carnitine	solution for intake, 300 mg/ml 100 ml
270	A16AA07	Metreleptin *	the powder lyophilized solution for injections
271	A16AB02	Imiglyutseraza *	solution lyophilisate for infusions, 400 ED
272	A16AB02	Imiglyutseraza *	solution lyophilisate for infusions, 200 ED
273	A16AB03	Agalsidaza alpha *	concentrate for solution for infusions, 1 mg/ml of 3,5 of ml
274	A16AB04	Agalsidaza beta *	lyophilisate for concentrate for solution for infusions, 35 mg
275	A16AB04	Agalsidaza beta *	lyophilisate for concentrate for solution for infusions, 5 mg
276	A16AB05	Laronidaza *	concentrate for solution for infusions, 100 PIECES/ml 5 ml
277	A16AB07	Alglyukozidaza *	solution concentrate powder for infusions of 50 mg
278	A16AB08	Galsulfaza *	concentrate for solution for infusions, 1 mg/ml 5 ml
279	A16AB09	Idursulfaza *	concentrate for solution for infusions, 2 mg/ml 3 ml
280	A16AB10	Velaglyutseraza alpha *	lyophilisate for solution for infusions, 400 ED
281	A16AB11	Taliglyutseraza alpha *	lyophilisate for solution for infusions, 200 ED
282	A16AB12	Elosulfaza alpha *	concentrate for solution for infusions, 1 mg/ml 5 ml
283	A16AB16	Idursulfaza beta	concentrate for solution for infusions, 2 mg/ml 3 ml
284	A16AX04	Nitizinon	capsule, 5 mg
285	A16AX04	Nitizinon	capsule, 10 mg
286	A16AX05	Zinc acetate *
287	A16AX06	Miglustat *
288	A16AX07	Sapropterin *	tablet, 100 mg
289	A16AX10	Eliglustat *
290	A16AX12	Trienoozes *	capsule, 250 mg
291	A16AX17	Trigeptanoin *
292	B01AA03	Varfarin **	tablet, mg 2,5
293	B01AA03	Varfarin **	tablet, 5 mg
294	B01AA03	Varfarin **	tablet, 3 mg
295	B01AB01	Sodium heparin **	solution for injections, 5000 PIECES/ml 5 ml
296	B01AB01	Sodium heparin **	solution for injections, 5000 PIECES/ml 10 ml
297	B01AB01	Sodium heparin **	solution for injections, 5000 ME/ml of 5 ml
298	B01AB02	Anti-thrombin III **	the powder lyophilized with the solvent for solution for intravenous administration, 500 ME
299	B01AB02	Anti-thrombin III **	the powder lyophilized with the solvent for solution for intravenous administration, 1000 ME
300	B01AB05	Enoksaparin of sodium **	solution in syringes for injections, 8000 Anti-ha ml ME/0,8
301	B01AB05	Enoksaparin of sodium **	solution in syringes for injections, 6000 Anti-ha ml ME/0,6
302	B01AB05	Enoksaparin of sodium **	solution in syringes for injections, 4000 Anti-ha ml ME/0,4
303	B01AB05	Enoksaparin of sodium **	solution in syringes for injections, 2000 Anti-ha ml ME/0,2
304	B01AB06	Nadroparin **	solution for injections, 3800ME of anti-Ha/0,4¼½
305	B01AB06	Nadroparin **	solution for injections, 7600 ME anti-Ha/0,8 of ml
306	B01AB06	Nadroparin **	solution for injections, 5700ME of anti-Ha/0,6¼½
307	B01AB06	Nadroparin **	solution for injections, 2850 ME anti-Ha/0,3 of ml
308	B01AB11	Sulodeksid	capsule, 250 LE
309	B01AB11	Sulodeksid	solution for injections, 600 LIE/2 ml
310	B01AC04	Klopidogrel **	tablet, 300 mg
311	B01AC04	Klopidogrel **	tablet, 75 mg
312	B01AC06	Acetilsalicylic acid **	tablet, 75 mg
313	B01AC06	Acetilsalicylic acid **	tablet, 100 mg
314	B01AC06	Acetilsalicylic acid **	tablet, 150 mg
315	B01AC06	Acetilsalicylic acid **	tablet, 300 mg
316	B01AC06	Acetilsalicylic acid **	tablet, 50 mg
317	B01AC07	Dipiridamol **	tablet, 25 mg
318	B01AC11	Iloprost *	solution for inhalations of 10 mkg/ml 1 ml
319	B01AC11	Iloprost *	solution for inhalations, 10 mkg/ml 2 ml
320	B01AC17	Tirofiban **	concentrate for solution for infusions, mg 12,5 / 50 ml
321	B01AC22	Prazugrel
322	B01AC23	Tsilostazol	tablet, 50 mg
323	B01AC23	Tsilostazol	tablet, 100 mg
324	B01AC24	Ticagrelor **	tablet, 90 mg
325	B01AC24	Ticagrelor **	tablet, 60 mg
326	B01AC27	Seleksipag *	tablet, 200 mkg
327	B01AC27	Seleksipag *	tablet, 400 mkg
328	B01AC27	Seleksipag *	tablet, 600 mkg
329	B01AC27	Seleksipag *	tablet, 800 mkg
330	B01AC27	Seleksipag *	tablet, 1000 mkg
331	B01AC27	Seleksipag *	tablet, 1400 mkg
332	B01AC27	Seleksipag *	tablet, 1200 mkg
333	B01AC27	Seleksipag *	tablet, 1600 mkg
334	B01AD01	Streptokinase **	the powder lyophilized for solution for injections, 1 500 000 ME
335	B01AD02	Alteplaza **	the powder lyophilized with the solvent for solution for intravenous infusions, 50 mg
336	B01AD04	Urokinaza **
337	B01AE06	Bivalirudin **
338	B01AE07	Dabigatrana eteksilat **	capsule, 110 mg
339	B01AE07	Dabigatrana eteksilat **	capsule, 75 mg
340	B01AE07	Dabigatrana eteksilat **	capsule, 150 mg
341	B01AF01	Rivaroksaban **	tablet, 10 mg
342	B01AF01	Rivaroksaban **	tablet, 15 mg
343	B01AF01	Rivaroksaban **	tablet, 20 mg
344	B01AF01	Rivaroksaban **	tablet, mg 2,5
345	B01AF02	Apiksaban **	tablet, mg 2,5
346	B01AF02	Apiksaban **	tablet, 5 mg
347	B01AF03	Edoksaban	tablet, 15 mg, 30 mg, 60 mg
348	B01AX05	Fondaparinuks sodium **	solution lyophilisate/powder for intravenous/hypodermic administration, ml 0,5 ml mg/0,5 2,5
349	B02AA01	Aminocaproic acid **	solution for infusions, 5% 100 ml
350	B02AA02	Traneksamovy acid **	solution for injections, 100mg/ml 5 ml
351	B02AA02	Traneksamovy acid **	solution for injections, 100 mg/ml 5 ml
352	B02AA02	Traneksamovy acid **	solution for injections, 100 mg/ml 10 ml
353	B02AA02	Traneksamovy acid **	solution for injections, 50 mg/ml 5 ml
354	B02AA02	Traneksamovy acid **	solution for injections, 50 mg/ml 10 ml
355	B02AA02	Traneksamovy acid **	tablet, 500 mg
356	B02AA02	Traneksamovy acid **	tablet, 250 mg
357	B02AA02	Traneksamovy acid **	capsule, 500 mg
358	B02AB01	Aprotinin **	solution for injections, 100 000 KIE of 10 ml
359	B02AB02	Alfa1 anti-trypsin *
360	B02BA01	Fitomenadion **	solution for intramuscular to introductions, 10 mg/ml 1 ml
361	B02BA02	Menadion **	solution for injections, 1% 1 ml
362	B02BC30	Combinations	the absorbing haemo static means, sponge the size 9, 5kh cm 4,8
363	B02BC30	Combinations	the absorbing haemo static means, sponge the size 4, 8kh cm 4,8
364	B02BC30	Combinations	the absorbing haemo static means, sponge the size 2, 5kh cm 3,0
365	B02BD01	Factor of fibrillation of II, VII, IX and X in combination **	the powder lyophilized with the solvent and set for introduction for solution for intravenous administration, 500 ME 20 ml
366	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 3000 ME 5 ml
367	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 3000 ME 2,5 of ml
368	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 3000 ME
369	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 2000 ME
370	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 2000 ME 5 ml
371	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 2000 ME 2,5 of ml
372	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent and set for introduction for solution for intravenous administration, 2000 ME 2,5 of ml
373	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent for solution for intravenous administration, 2000 ME
374	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 2000 ME
375	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1500 ME, 5 ml
376	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1500 ME 2 ml
377	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 1500 ME
378	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME
379	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME,10 of ml
380	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME, 10 ml
381	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 1000 ME, 10 ml
382	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for infusions, 1000 ME, 10 ml
383	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 1000 ME, 5 ml
384	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for infusions, 1000 ME, 5 ml
385	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent and set for introduction for solution for intravenous administration, 1000 ME, 2,5 ml
386	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME 2,5 of ml
387	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME, 2 ml
388	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME 2 ml
389	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent for solution for intravenous administration, 1000 ME
390	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 1000 ME
391	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 750 ME
392	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 500 ME
393	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 500 ME 5 ml
394	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 500 ME
395	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 500 ME 2,5 of ml
396	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 500 ME 2 ml
397	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 500 ME
398	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 500 ME
399	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for infusions, 500 ME
400	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent for solution for intravenous administration, 500 ME
401	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent and set for introduction for solution for intravenous administration, 500 ME
402	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 500 ME
403	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent and set for introduction for solution for intravenous administration, 250 ME
404	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized with the solvent for solution for intravenous administration, 250 ME
405	B02BD02	Factor of fibrillation of VIII **	the powder lyophilized for injections, 250 ME
406	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 250 ME 5 ml
407	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 250 ME 2,5 of ml
408	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 250 ME, 2 ml
409	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 250 ME
410	B02BD02	Factor of fibrillation of VIII **	lyophilisate with the solvent for solution for intravenous administration, 250 ME
411	B02BD03	Inhibitor of destruction of factor of fibrillation VIII **	lyophilisate with the solvent and set for solution for infusions, 1000 ED
412	B02BD03	Inhibitor of destruction of factor of fibrillation VIII **	lyophilisate with the solvent and set for solution for infusions, 500 ED
413	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for injections, 3000 ME
414	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for solution for intravenous administration, 2000 ME
415	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for injections, 2000 ME
416	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for infusions, 1500 ME
417	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for infusions, 1200 ME
418	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for infusions, 1000 ME
419	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for intravenous administration, 1000 ME
420	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for solution for intravenous administration, 1000 ME
421	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent and set for introduction for solution for infusions, 1000 ME
422	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for injections, 1000 ME
423	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for infusions, 600 ME
424	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for solution for intravenous administration, 500 ME
425	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent and set for introduction for solution for infusions, 500 ME
426	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for injections, 500 ME
427	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for intravenous administration, 500 ME
428	B02BD04	Factor of fibrillation of IX **	lyophilisate with the solvent for solution for infusions, 500 ME
429	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent for solution for intravenous administration, 250 ME
430	B02BD04	Factor of fibrillation of IX **	the powder lyophilized with the solvent and set for introduction for solution for infusions, 250 ME
431	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent for solution for intravenous administration, 2400 ME + 1000 ME
432	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent for solution for intravenous administration, 1200 ME + 500 ME
433	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate for solution for intravenous administration, 1000 ME
434	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent for solution for infusions, 1000 ME
435	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 1000 ME
436	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 900 ME
437	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent for solution for intravenous administration, 600 ME + 250 ME
438	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 500 ME
439	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate for solution for intravenous administration, 500 ME
440	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent for solution for infusions, 500 ME
441	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent and set for introduction for solution for intravenous administration, 450 ME
442	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate for solution for intravenous administration, 250 ME
443	B02BD06	Villebrand's factor and factor of fibrillation of VIII in combination **	lyophilisate with the solvent for solution for infusions, 250 ME
444	B02BD08	VIIA fibrillation factor **	lyophilisate with the solvent for solution for intravenous administration, mg 4,8
445	B02BD08	VIIA fibrillation factor **	lyophilisate with the solvent for solution for intravenous administration, mg 2,4
446	B02BD08	VIIA fibrillation factor **	lyophilisate with the solvent for solution for intravenous administration, mg 1,2
447	B02BX01	Etamsylate **	tablet, 250 mg
448	B02BX01	Etamsylate **	solution for intravenous/intramuscular administration of 12,5 of % of 2 ml
449	B02BX01	Etamsylate **	Solution for injections, 12,5 of % of 2 ml
450	B02BX01	Etamsylate **	solution for injections, 250 mg / 2 ml
451	B02BX04	Romiplostim *	powder for solution for hypodermic introduction, 250 mkg
452	B02BX05	Eltrombopag *	tablet, 25 mg
453	B02BX05	Eltrombopag *	tablet, 50 mg
454	B02BX06	Emitsizumab *	solution for injections, 105 mg / 0,7 of ml
455	B02BX06	Emitsizumab *	solution for injections, 30 mg / 1 ml
456	B02BX06	Emitsizumab *	solution for injections, 60 mg / 0,4 of ml
457	B02BX06	Emitsizumab *	solution for injections, 150 mg / 1 ml
458	B03AA	Medicines of iron (bivalent) for intake	syrup, 100 ml
459	B03AA	Medicines of iron (bivalent) for intake	drops for intake, 30 ml
460	B03AA	Medicines of iron (bivalent) for intake	tablet, 320 mg / 60 mg
461	B03AA07	Gland sulfate	drops for intake, 25 ml
462	B03AA07	Gland sulfate	tablet, 80 mg
463	B03AC	Iron medicines parenteral **	solution for injections, 20 mg/ml, 5 ml
464	B03AC	Iron medicines parenteral **	solution for injections, 50 mg/ml, 2 ml
465	B03AC	Iron medicines parenteral **	solution for injections, 50 mg/ml, 10 ml
466	B03AC	Iron medicines parenteral **	solution for intravenous administration, 2 g / 5 ml of 5 ml
467	B03AD02	Gland fumarat and Folic acid	capsule, 152, 1mg/0,54¼ú
468	B03AD03	Gland sulfate and Folic acid	tablet, 80 mg / mg 0,35
469	B03AE10	Other combinations	syrup, 100 ml
470	B03AE10	Other combinations	tablet, 320 mg / 60 mg
471	B03AE10	Other combinations	solution for intake, 10 ml
472	B03BA01	Cyanocobalamine **	solution for injections, 200 mkg/ml 1 ml
473	B03BA01	Cyanocobalamine **	solution for injections, 500 mkg/ml 1 ml
474	B03BA01	Cyanocobalamine **	tablet, 1 mg
475	B03BB01	Folic acid **	tablet, 5 mg
476	B03BB01	Folic acid **	tablet, 1 mg
477	B03BB01	Folic acid **	tablet, 400 mkg
478	B03XA01	Erythropoietin / Epoetin alpha **	solution for injections, 40000 ME/1 ml
479	B03XA01	Erythropoietin **	solution for injections, 40000 ME/1 ml
480	B03XA01	Erythropoietin **	solution for injections, 2000 ME/0,5 ml
481	B03XA01	Erythropoietin **	solution for injections, 2000 ME/1 ml
482	B03XA01	Erythropoietin **	solution for injections, 2000 ME/0,3 ml
483	B03XA01	Erythropoietin **	solution for injections, 2000 ME/0,6 ml
484	B03XA01	Erythropoietin **	solution for injections, 1000 ME/0,5 ml
485	B03XA01	Erythropoietin **	solution for injections, 4000 ME/0,4 ml
486	B03XA01	Erythropoietin **	solution for injections, 1000 ME/0,3 ml
487	B03XA01	Erythropoietin **	solution for injections, 6000 ME/0,6 ml
488	B03XA01	Erythropoietin **	solution for injections, 10 000 ME/1 of ml
489	B03XA02	Darbepoetin alpha **	solution for injections, 500 mkg 1 ml
490	B03XA02	Darbepoetin alpha **	solution for injections, 30 mkg of 0,3 of ml
491	B03XA02	Darbepoetin alpha **	solution for injections, 20 mkg of 0,5 of ml
492	B03XA02	Darbepoetin alpha **	solution for injections, 10 mkg of 0,4 of ml
493	B03XA03	Metoks polyethyleneglycol-epoetina beta	solution for intravenous/subcutaneous injections, 75 mkg / 0,3 of ml
494	B03XA03	Metoks polyethyleneglycol-epoetina beta	solution for intravenous/subcutaneous injections, 50 mkg / 0,3 of ml
495	B05AA01	Albumine **	solution for infusions, 5% 100 ml
496	B05AA01	Albumine **	solution for infusions, 5% 250 ml
497	B05AA01	Albumine **	solution for infusions, 5% 500 ml
498	B05AA01	Albumine **	solution for infusions, 10% 100 ml
499	B05AA01	Albumine **	solution for infusions, 10% 50 ml
500	B05AA01	Albumine **	solution for infusions, 10% 20 ml
501	B05AA01	Albumine **	solution for infusions, 20%100 ml
502	B05AA01	Albumine **	solution for infusions, 20% 100 ml
503	B05AA01	Albumine **	solution for infusions, 20% 50 ml
504	B05AA01	Albumine **	solution for infusions, 25% 50 ml
505	B05AA01	Albumine **	solution for infusions, 25% 100 ml
506	B05AA05	Dextran **	solution for infusions, 10% 200 ml
507	B05AA05	Dextran **	solution for infusions, 10% 400 ml
508	B05AA05	Dextran **	solution for infusions, 6% 200 ml
509	B05AA05	Dextran **	solution for infusions, 6% 400 ml

Warning!!!

This is not a full text of document! Document shown in Demo mode!

If you have active License, please Login, or get License for Full Access.

With Full access you can get: full text of document, original text of document in Russian, attachments (if exist) and see History and Statistics of your work.

Get License for Full Access Now

Disclaimer! This text was translated by AI translator and is not a valid juridical document. No warranty. No claim. More info

Effectively work with search system

Database include more 50000 documents. You can find needed documents using search system. For effective work you can mix any on documents parameters: country, documents type, date range, teams or tags.
More about search system

Get help

If you cannot find the required document, or you do not know where to begin, go to Help section.

In this section, we’ve tried to describe in detail the features and capabilities of the system, as well as the most effective techniques for working with the database.

You also may open the section Frequently asked questions. This section provides answers to questions set by users.